Perhaps. But if it's so obvious, won't it be an open-and-shut case?

It should be a big deal. We really don't want drug companies being able to skip to a position on effectiveness that is convenient for marketing reasons.

It's not like Pfizer are short of cash to defend themselves.

If it starts to become a money pit, then it means there's a knotty issue to be solved, and that's important to know about.